Respiratorius AB (publ) (XSAT:RESP)
Sweden · Delayed Price · Currency is SEK 1.740
+0.120 (7.41%)
At close: Jan 2, 2026
Respiratorius AB Company Description
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer.
The company’s products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma.
Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.
Respiratorius AB (publ)
| Country | Sweden |
| Founded | 1998 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 1 |
| CEO | Johan Drott |
Contact Details
Address: Medicon Village Lund, 223 81 Sweden | |
| Phone | 46 7 09 22 41 40 |
| Website | respiratorius.com |
Stock Details
| Ticker Symbol | RESP |
| Exchange | Spotlight Stock Market |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Johan Drott | Chief Executive Officer |